Price
$0.7031
Decreased by -0.97%
Dollar Volume
209.94 K
ADR%
8.63
Earnings Report Date (estimate)
Mar 29, 23 (-0.15)
Market Cap.
22.94 M
Shares Float
17.06 M
Shares Outstanding
32.63 M
Beta
0.30
Price / Earnings
-1.05
BPR
77.83
20D Range
0.70 1.07
50D Range
0.60 1.87
200D Range
0.50 2.90
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 14, 22 -0.11
Decreased by -57.14%
-0.12
Increased by +8.33%
Oct 14, 22 -0.06
Increased by +25.00%
-0.12
Increased by +50.00%
Aug 15, 22 -0.06
Increased by +75.00%
-0.20
Increased by +70.00%
Mar 31, 22 -0.31 -0.04
Decreased by -675.00%
Nov 15, 21 -0.07 -0.04
Decreased by -75.00%
Aug 12, 21 -0.08 -0.04
Decreased by -100.00%
Mar 16, 21 -0.24 -0.10
Decreased by -140.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 42.27 K
Decreased by -57.30%
-3.70 M
Decreased by -105.09%
Decreased by -8.76 K%
Decreased by -380.34%
Jun 30, 22 312.86 K
Increased by +895.07%
-1.86 M
Increased by +5.71%
Decreased by -594.19%
Increased by +90.52%
Mar 31, 22 25.66 K
Decreased by -90.25%
-6.00 M
Decreased by -431.27%
Decreased by -23.36 K%
Decreased by -5.35 K%
Dec 31, 21 -37.79 K
Decreased by -160.77%
-7.93 M
Decreased by -63.61%
Increased by +20.99 K%
Increased by +369.24%
Sep 30, 21 99.00 K
Decreased by -14.33%
-1.81 M
Increased by +2.14%
Decreased by -1.82 K%
Decreased by -14.22%
Jun 30, 21 31.44 K
Decreased by -86.12%
-1.97 M
Decreased by -6.61%
Decreased by -6.27 K%
Decreased by -668.07%
Mar 31, 21 263.15 K
Increased by +234.01%
-1.13 M
Increased by +9.54%
Decreased by -428.84%
Increased by +72.92%
Dec 31, 20 62.19 K
Decreased by -37.78%
-4.85 M
Decreased by -349.89%
Decreased by -7.80 K%
Decreased by -623.09%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.